Navigation Links
Cardiogenesis Reports Second Quarter 2009 Results

IRVINE, Calif., Aug. 13 /PRNewswire-FirstCall/ -- Cardiogenesis Corporation (Pink Sheets: CGCP), a leading developer of surgical products used in the treatment of patients suffering from severe angina, today reported financial results for its second quarter ended June 30, 2009.

Net revenues in the second quarter of 2009 totaled $2,236,000, a 46% decrease from the prior year second quarter net revenues of $4,119,000. The decrease in net revenue for the three months ended June 30, 2009 results primarily from the absence of laser sales in the current year quarter.

Net revenues in the first six months of 2009 totaled $5,088,000, a decrease of approximately 28% from net revenues of $7,101,000 in the first six months of 2008. The year to date decrease as compared with the prior year period is primarily attributable to a $1,459,000, or 66%, decrease in laser sales and a $635,000, or 15%, decrease in disposable handpiece revenue.

Paul McCormick, Executive Chairman, noted, "Although we face a very challenging capital equipment environment, we are pleased to note that total domestic handpiece revenue was up sequentially, which we believe to be an early response to our marketing strategy to focus on building the revenue stream from its consumables by re-engaging the cardiology community. We plan on providing more detail on our growth strategies on today's conference call."

The Company reported a second quarter 2009 operating loss of $562,000 as compared with an operating income of $582,000 in the prior year quarter. The net loss for the quarter was $590,000 or $0.01 per basic and diluted share, as compared with net income of $602,000, or $0.01 per basic and diluted share in the 2008 second quarter.

For the first six months of 2009, Cardiogenesis reported an operating loss of $859,000 as compared with operating income of $545,000 for the same period in the prior year. The net loss for the first six months of 2009 was $904,000, or $0.02 per basic and diluted share, compared with net income of $566,000, or $0.01 per basic and diluted share, for the first six months of 2008.

The gross margin percentage was 83% of net revenues for the quarter ended June 30, 2009 as compared with 86% in the second quarter of 2008. Gross profit in absolute dollars decreased by $1,684,000 to $1,845,000 for the current year second quarter as compared with $3,529,000 for the 2008 second quarter.

For the six months ended June 30, 2009, the gross margin percentage was 82% of net revenues as compared to 84% for the six months ended June 30, 2008. Gross profit in absolute dollars decreased by $1,825,000 to $4,161,000 for the six months ended June 30, 2009, as compared to $5,986,000 for the six months ended June 30, 2008. The decrease in the gross margin percentage and gross profit in dollars for the six month period is primarily attributed to a decrease in laser sales.

Research and development expenses were $346,000 in the second quarter of 2009 as compared with $252,000 in the 2008 second quarter. Year to date, R&D expenses of $634,000 were $166,000 or 35% above the prior year period of $468,000. The dollar increase for the three and six months ended June 30, 2009 was primarily attributed to the recent submissions to the Food and Drug Administration related to the Premarket Approval Application for the PEARL 8.0 handpiece and the pre-Investigational Device Exemption to initiate a feasibility trial for the PHOENIX handpiece.

Sales and marketing expenses of $1,272,000 in the quarter ended June 30, 2009 decreased $523,000, or 29%, compared with $1,795,000 for the quarter ended June 30, 2008. For the six months ended June 30, 2009, S&M expenditures totaled $2,741,000, a decrease of $581,000, or 17%, compared with $3,322,000 for the six months ended June 30, 2008. The decrease in sales and marketing expenditures for the three and six months ended June 30, 2009 was primarily due to a decrease in salary and other employee related expenses as a result of lower commissions and decreased travel expense.

General and administrative expenses for the quarter ended June 30, 2009 totaled $789,000 as compared to $900,000 during the quarter ended June 30, 2008. This represents a decrease of $111,000, or 12%. For the six months ended June 30, 2009, G&A totaled $1,645,000 as compared to $1,651,000 for the six months ended June 30, 2008. This represents a reduction of $6,000, or less than 1%.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that treat severe angina. Our market leading holmium:YAG laser system and single use fiber-optic delivery systems are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR).

For more information on Cardiogenesis and its products, please visit our website at or the direct to patient website at

Safe Harbor Statement

With the exception of historical information, the statements set forth above include forward-looking statements. Any forward-looking statements in this news release are subject to numerous risks and uncertainties, many of which are outside the Company's control, that could cause actual results to differ materially. Factors that could affect the accuracy of these forward-looking statements include, but are not limited to: any inability by the Company to sustain profitable operations or obtain additional financing on favorable terms if and when needed; any failure to obtain required regulatory approvals; failure of the medical community to expand its acceptance of TMR procedures; possible adverse governmental rulings or regulations, including any FDA regulations or rulings; the Company's ability to comply with international and domestic regulatory requirements; possible adverse Medicare or other third-party reimbursement policies or adverse changes in those policies; any inability by the Company to ship product on a timely basis; the Company's ability to manage its growth; the effects of recent disruptions in global credit and equity markets and other adverse economic developments that could adversely affect the market for our products or our ability to raise needed financing; actions by our competitors; and the Company's ability to protect its intellectual property. Other factors that could cause Cardiogenesis' actual results to differ materially are discussed in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2008 and the Company's other filings with the Securities and Exchange Commission. The Company disclaims any obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

                              CARDIOGENESIS CORPORATION
                        (in thousands, except per share amounts)

                                         Three months ended  Six months ended
                                              June 30,           June 30,
                                           2009      2008     2009     2008
                                           ----      ----     ----     ----
    Net revenues                          $2,236   $4,119   $5,088   $7,101
    Cost of revenues                         391      590      927    1,115
                                             ---      ---      ---    -----
        Gross profit                       1,845    3,529    4,161    5,986
                                           -----    -----    -----    -----
    Operating expenses:
      Research and development               346      252      634      468
      Sales and marketing                  1,272    1,795    2,741    3,322
      General and administrative             789      900    1,645    1,651
                                             ---      ---    -----    -----
        Total operating expenses           2,407    2,947    5,020    5,441
                                           -----    -----    -----    -----
        Operating income (loss)             (562)     582     (859)     545
    Other income (expense):
    Interest expense                         (21)      (1)     (31)     (21)
    Interest income                            1       21        2       42
                                             ---      ---      ---      ---
    Total other income (expense), net        (20)      20      (29)      21
                                            ----       --     ----       --
        Income (loss) before income taxes   (582)     602     (888)     566
    Provision for income taxes                 8        -       16        -
                                             ---      ---      ---      ---
        Net income (loss)                   (590)     602     (904)     566
                                           =====      ===    =====      ===
    Net earnings (loss) per share:
      Basic                               $(0.01)   $0.01   $(0.02)   $0.01
                                          ======    =====   ======    =====
      Diluted                             $(0.01)   $0.01   $(0.02)   $0.01
                                          ======    =====   ======    =====

    Weighted average shares outstanding:
      Basic                               45,519   45,293   45,503   45,284
                                          ------   ------   ------   ------
      Diluted                             45,519   45,306   45,503   45,313
                                          ------   ------   ------   ------

                             CARDIOGENESIS CORPORATION
                                   (in thousands)

                                                       June 30,  December 31,
                                                         2009        2008
                                                      (unaudited)  (audited)
                                                      -----------   --------

    Current assets:
      Cash and cash equivalents                           $2,709      $2,907
      Accounts receivable, net of allowance for
       doubtful accounts of $7 and $20, respectively         991       1,330
      Inventories                                          1,036       1,164
      Investments in marketable securities                     -          75
      Prepaids and other current assets                      289         395
                                                             ---         ---
        Total current assets                               5,025       5,871
    Property and equipment, net                              397         382
    Other assets, net                                         18          18
                                                             ---         ---
        Total assets                                      $5,440      $6,271
                                                          ======      ======


    Current liabilities:
      Accounts payable                                      $322        $200
      Accrued liabilities                                    936       1,103
      Deferred revenue                                       799         800
      Current portion of capital lease obligations             9           6
                                                             ---         ---
        Total current liabilities                          2,066       2,109
    Capital lease obligations, less current portion           19          13
                                                             ---         ---
        Total liabilities                                  2,085       2,122
                                                           -----       -----

    Commitments and Contingencies

    Shareholders' equity:
      Preferred stock:
        no par value; 5,000 shares authorized;
         none issued and outstanding                           -           -
      Common stock:
        no par value; 75,000 shares authorized;
         45,549 and 45,487 shares issued and
         outstanding, respectively                       174,109     173,999
      Accumulated deficit                               (170,754)   (169,850)
                                                        --------    --------
        Total shareholders' equity                         3,355       4,149
                                                           -----       -----
        Total liabilities and shareholders' equity        $5,440      $6,271
                                                          ======      ======

SOURCE Cardiogenesis Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiogenesis Corporation Names Paul J. McCormick Executive Chairman
2. Cardiogenesis Reports First Quarter 2009 Results
3. Cardiogenesis Reports Fourth Quarter and Fiscal Year 2008 Results
4. Cardiogenesis Corporation to Report 2008 Fourth Quarter and Year-End Results on March 31st
5. Cardiogenesis Announces Successful Educational Symposium at Society of Thoracic Surgeons Meeting in San Francisco
6. Cardiogenesis Corporation to Report Third Quarter 2008 Results on November 13th
7. Cardiogenesis Announces Successful Educational Symposium Targeted at Cardiologists at the TCT Meeting in Washington, D.C.
8. Cardiogenesis Announces Preliminary Results Combining TMR + Platelet Rich Plasma (PRP)
9. Cardiogenesis Reports First Quarter 2008 Results
10. Cardiogenesis Corporation to Report 2008 First Quarter Results on May 15th
11. Cardiogenesis Corporation Announces Rescheduled Fourth Quarter and Full Year 2007 Earnings Release
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of indulgence ... high can result in disappointment, perhaps even self-loathing. However, those who set the bar ... from reveals that behind the tendency to set low expectations is ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... , June 27, 2016  VMS Rehab Systems, Inc. ... will take whatever measures required to build a strong ... which is currently listed on the OTC Markets-pink current ... Chairman and CEO, "We are seeing an anomaly in ... understand, not only by the Company, but shareholders and ...
Breaking Medicine Technology: